News

Articles

The acquisition gives Merck a new Phase III COVID-19 therapeutic candidate, CD24Fc, a fusion protein that targets the innate immune system, in its pipeline.

Merck to Acquire OncoImmune for $425 Million

An independent data safety monitoring board found that clinical trial data demonstrated that the vaccine candidate met its primary endpoint and demonstrated protection from COVID-19.

AstraZenca Vaccine Candidate ‘Highly-Effective’ in Preventing COVID-19

The new facility, which is expected to be operational by mid-2026, will utilize cell-based technology to produce influenza vaccines for influenza pandemics and seasonal vaccination programs, both in Australia and globally. 

Seqirus to Invest $584 Million in Australian Biotech Manufacturing Facility

FDA issued emergency use authorization for bamlanivimab for patients at risk for severe COVID-19.

Lilly’s COVID-19 mAb Treatment Receives EUA

The agreement provides Novo Nordisk with full access to Emisphere’s Eligen SNAC technology, which will boost Novo Nordisk’s portfolio of oral therapeutics. 

Novo Nordisk to Acquire Emisphere Technologies for $1.8 Billion

Interim efficacy data suggests the Pfizer/BioNTech mRNA-based vaccine has an efficacy rate above 90%.

Pfizer: COVID-19 Vaccine Shows High Efficacy	

Through the acquisition, Merck will gain access to VelosBio’s lead investigational candidate, VLS-101, an antibody-drug conjugate that targets receptor tyrosine kinase-like orphan receptor 1.

Merck to Acquire VelosBio for $2.75 Billion

Bayer will own the rights to AskBio’s AAV-based gene therapy platform, its intellectual property portfolio, and an established CDMO.

Bayer to Acquire AskBio for up to $4 Billion

Gilead’s antiviral drug Veklury is the first approved treatment in the US for COVID-19.

FDA Approves Remdesivir for Hospitalized Patients

200 employees will be hired by the end of 2020, with 300 more planning to be hired by 2023. 

Top News